- Home
- TNXP vs DMB Comparison
TNXP vs DMB Comparison
Compare TNXP & DMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- DMB
- Stock Information
- Founded
- TNXP 2007
- DMB 2013
- Country
- TNXP United States
- DMB United States
- Employees
- TNXP N/A
- DMB N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- DMB Trusts Except Educational Religious and Charitable
- Sector
- TNXP Health Care
- DMB Finance
- Exchange
- TNXP Nasdaq
- DMB Nasdaq
- Market Cap
- TNXP 207.5M
- DMB 185.2M
- IPO Year
- TNXP N/A
- DMB N/A
- Fundamental
- Price
- TNXP $33.33
- DMB $10.03
- Analyst Decision
- TNXP Strong Buy
- DMB
- Analyst Count
- TNXP 2
- DMB 0
- Target Price
- TNXP $585.00
- DMB N/A
- AVG Volume (30 Days)
- TNXP 1.1M
- DMB 76.6K
- Earning Date
- TNXP 08-15-2025
- DMB 01-01-0001
- Dividend Yield
- TNXP N/A
- DMB 4.17%
- EPS Growth
- TNXP N/A
- DMB N/A
- EPS
- TNXP N/A
- DMB N/A
- Revenue
- TNXP $10,041,000.00
- DMB N/A
- Revenue This Year
- TNXP $11.66
- DMB N/A
- Revenue Next Year
- TNXP $793.18
- DMB N/A
- P/E Ratio
- TNXP N/A
- DMB N/A
- Revenue Growth
- TNXP N/A
- DMB N/A
- 52 Week Low
- TNXP $6.76
- DMB $8.94
- 52 Week High
- TNXP $137.25
- DMB $11.79
- Technical
- Relative Strength Index (RSI)
- TNXP 52.50
- DMB 41.78
- Support Level
- TNXP $33.41
- DMB $9.97
- Resistance Level
- TNXP $37.42
- DMB $10.14
- Average True Range (ATR)
- TNXP 3.48
- DMB 0.07
- MACD
- TNXP -1.12
- DMB 0.00
- Stochastic Oscillator
- TNXP 33.66
- DMB 16.26
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.